文本框: THE CHANGE OF TISSUE FACTOR AND TISSUE FACTOR PATHWAY INHIBITOR IN NEONATAL INFECTION JAUNDICE Yue Sh-J1, Zhong L1, He X-F2, Yang Y-J,1 Jiang L1, He Sh-L2, Li J-Ch2 1 Department of Pediatrics, Xiangya Hospital, Changsha, China 2 Department of Physiology, Central South University, Changsha, China Objective: To study the change of tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in plasma of newborn with infection jaundice. Methods: The content of TF and TFPI of plasma in 21 jaundiced newborns with infection and 8 jaundiced newborns without infection as control were determined quantitatively by immunoenzymatic assay. Results: The level of TFPI and TF of infection infants were significantly higher than the controls (TFPI 21.00±4.27 vs. 16.18±1.86 µg/l, p<0.01,TF 176.77±79.09 vs. 16.18±1.86ng/l,p<0.01）,TFPI/TF was significantly lower than the controls (137.27±61.20 vs. 318.71±67.21, P<0.01）.21 jaundiced newborn with infection were divided into severe jaundice group (serum bilirubin>12mg/ dl,n=10) and the mild jaundice group (serum bilirubin<12mg/dl, n=11）.There is no significant difference of TFPI level between severe group and mild group (p>0.05). TF level in severe group was higher than mild group (216.21±78.72 vs.140.91±62.96, P<0.01), while TFPI/TF lower than mild group (99.66±30.19 vs. 171.49±74.20). Conclusion: Infection could induce imbalance between the coagulation inhibition and activation in newborn. Hyperbilirubinemia could aggravate the imbalance by enhancing TF expression in the body. Recombinant TFPI may be effective as a treatment for severe jaundiced newborns with infection to restore the balance between coagulation inhibition and coagulation activation and to prevent DIC. 0951